EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.23.24 | Acquired Immunodeficiency Syndrome |
7952656 |
Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors. |
causal interaction |
1 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
10395861 |
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. |
causal interaction |
4 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
15305695 |
[Highly Active AntiRetroviral Therapy and cryptosporidiosis] |
causal interaction |
2 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
30393404 |
Syntheses of FDA Approved HIV Protease Inhibitors. |
causal interaction |
3 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
32601166 |
The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus. |
causal interaction |
2 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
10395861 |
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. |
therapeutic application |
4 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
10770752 |
Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. |
therapeutic application |
1 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
15305695 |
[Highly Active AntiRetroviral Therapy and cryptosporidiosis] |
therapeutic application |
4 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
30393404 |
Syntheses of FDA Approved HIV Protease Inhibitors. |
therapeutic application |
4 |
| 3.4.23.24 | Acquired Immunodeficiency Syndrome |
32601166 |
The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus. |
therapeutic application |
4 |
